Market Overview

UPDATE: Jefferies Raises PT to $104 on ONYX Pharmaceuticals on Kyprolis Survey Data

Related ONXX
How to Prepare for the New Year
UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen

Jefferies maintained ONYX Pharmaceuticals (NASDAQ: ONXX) with a Buy rating and raised the price target from $96.00 to $104.00.

Jefferies analyst Biren Amin commented, "Based on recent events incl frontline data and NCCN Compendium listing, and Pomalyst launch, we conducted a follow-up survey in myeloma, and observed 1st/2nd line Kyprolis use could be significantly higher than consensus. We raise our Kyprolis sales projections with a new $104 PT (v $96 previously)."

ONYX Pharmaceuticals closed at $86.61 on Monday.

Latest Ratings for ONXX

Nov 2013Stifel NicolausTerminates
Aug 2013Maxim GroupDowngradesBuyHold
Aug 2013Summer StreetDowngradesBuyNeutral

View More Analyst Ratings for ONXX
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (ONXX)

View Comments and Join the Discussion!

Partner Center